SWEDISH ORPHAN BIOVITRUM AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 283.6 SEK | +1.00% |
|
-0.63% | +6.22% |
| May. 08 | Sobi Finalizes Inaugural SEK3 Billion Bond Issue | MT |
| May. 08 | Sobi Secures Additional EU Indication for Rare Blood Disorder Therapy | MT |
Presentation Operator MessageOperator (Operator)Ladies and gentlemen, welcome to the Sobi Q4 a...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Swedish Orphan Biovitrum publ AB is a Sweden-based pharmaceutical company. The Company develops, manufactures and sells medications within hemophilia, autoimmune diseases, metabolic diseases and cancer supportive care. The Companyâs product portfolio is divided into three business segments: the Core Products segment offers pharmaceuticals within Inflammation area, and Genetics and metabolic therapeutic area; the Partner Products segment offers about 40 pharmaceuticals within hematology, oncology and emergency medicines, and the ReFacto Manufacturing segment. The Company has subsidiaries in Sweden, Denmark, Finland, Norway, United Kingdom and France, among others. On September 9, 2013, the Company acquired the full rights to develop and commercialize Kineret (anakinra) from Amgen, the biotechnology company based in the United States.
Sector
Pharmaceuticals
Calendar
2024-05-14
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
283.6
SEK
Average target price
317.8
SEK
Spread / Average Target
+12.05%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +6.22% | 8.84B | |
| -2.76% | 88.91B | |
| +2.76% | 41.25B | |
| -13.92% | 31.99B | |
| +50.51% | 24.73B | |
| -15.25% | 15.54B | |
| -39.93% | 12.07B | |
| -9.08% | 12.05B | |
| -14.80% | 12.02B | |
| -4.33% | 8.3B |
- Stock Market
- Equities
- SOBI Stock
- News Swedish Orphan Biovitrum AB
- Transcript : Swedish Orphan Biovitrum AB, Q4 2021 Earnings Call, Feb 10, 2022